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When Evaluating Parameter Uncertainty Is Not Enough: The Case of
Dasatinib and Nilotinib for Imatinib-Resistant Chronic Myeloid LeukemiaChronic myeloid leukemia (CML) accounts for one in five cases of
leukemia in adults [1]. Tyrosine kinase inhibitors (TKIs) have rev-
olutionized the treatment paradigm for CML. The first, imatinib
(Gleevec/Glivec), was approved in 2002 by the U.S. Food and Drug
Administration and the European Agency for the Evaluation of
Medicinal Products. Although data on the long-term effectiveness
of imatinib were sparse, early cost-effectiveness analyses based
on conservative associations between short-term cytogenetic re-
sponse and long-term quality-adjusted survival indicated that its
use in chronic-phase disease was of good value, despite a cost of
$29,000 per year in 2002 [2]. Consistent with these findings, guid-
ance from the U.K. National Institute for Health and Clinical Ex-
cellence recommends the use of standard-dose imatinib (400
mg/d) as first-line therapy for chronic-phase CML [3].
Some patients do not respond to standard-dose imatinib (i.e.,
primary resistance), and some patients lose their response (i.e.,
secondary resistance). In the landmark International Randomized
Study of Interferon and STI571, approximately one in four patients
had primary resistance at 18 months [4]; by 5 years, one in four
patients had developed secondary resistance [5]. Although stem
cell transplant is an option, many patients are not appropriate
candidates. Other options include interferon alfa and hy-
droxyurea/hydroxycarbamide, but increasing the dose of imatinib
to 600 or 800 mg/d or switching to treatment with a second-gen-
eration TKI is considered to be more effective [6].
Two second-generation TKIs are approved for the treatment of
patientswith resistance to imatinib: dasatinib (Sprycel) and nilotinib
(Tasigna). Although a single randomized clinical trial compared da-
satinib to high-dose imatinib in patientswith imatinib resistance [7],
adequately powered head-to-head trials of nilotinib and dasatinib
have not been conducted [6]. Furthermore, dissimilarities in inclu-
sion criteria, study designs, and variations in end-point definitions
across studies impede the ability tomake high-quality direct or indi-
rect comparisons [6]. On the basis of best available evidence, clinical
experts consider the expected clinical outcomes with dasatinib and
nilotinib for second-line treatment to be similar [6,8,9].
In this issue of Value in Health, Hoyle et al. report survival esti-
mates from a decision-analytic model designed to evaluate the
cost-effectiveness of nilotinib and dasatinib in comparison with
high-dose imatinib for second-line treatment of CML. Among pa-
tients with resistance to imatinib, expected survival was an esti-
mated 12.4 years with high-dose imatinib, 13.4 years with dasat-
inib, and 13.0 yearswith nilotinib. Although the survival estimates
for nilotinib and dasatinib were slightly greater than for high-dose
imatinib, all three estimates had 95% confidence intervals ranging
from 8 to 17 years. Cumulative discounted costs for high-dose
imatinib and nilotinib were an estimated £89,000 and £70,000, re-
spectively, approximately half of the £161,000 estimated for sec-
ond-line dasatinib. Although the authors report that nilotinib
dominated high-dose imatinib (i.e., was less costly and more ef-fective), the incremental cost-effectiveness ratio for dasatinib
compared with that for imatinib was an estimated £91,500 per
quality-adjusted life-year. One possible explanation is that the
price of dasatinib was approximately double the price of nilotinib.
However, themonthly cost applied to dasatinib was slightly lower
(£1169) than the cost applied to nilotinib (£1217).
If two drugs are thought to be equally effective and their costs
are similar, whywould an economic evaluation show that onewas
economically dominant and the incremental cost-effectiveness
ratio for the other vastly exceeded the £30,000 per quality-ad-
justed life-year mark compared with high-dose imatinib? The
short answer is that patients were assumed to take second-line
high-dose imatinib and nilotinib for just 2.7 and 2.4 years, respec-
tively, compared with 6.5 years for patients receiving second-line
dasatinib. The authors lacked direct information about treatment
duration, and so they derived estimates of treatment duration
from estimates of progression-free survival and 3-month discon-
tinuation rates. For patients with imatinib resistance, progression-
free survival was an estimated 0.63 at 18 months for nilotinib and
0.77 at 2 years for dasatinib. Although direct comparisons are rife
with limitations, there appears to be an advantage with dasatinib.
Nevertheless, this potential advantage gave rise to longer treatment
duration with dasatinib, resulting in considerably higher costs and
qualitatively different findings with regard to cost-effectiveness.
Overreliance on probabilistic sensitivity analysis?
Nearly 10 years ago, the ISPOR Good Research Task Force pub-
lished recommendations on decision-analytic modeling [10]. Al-
though numerous specific recommendations were included, Gar-
rison’s [11] summary was simple: models should be transparent
and reasonable.Without specific information about treatment du-
ration, itmayhave been reasonable to apply a proxy.Most patients
with CML will continue to receive TKIs until disease progression
and for some time thereafter [8]. Therefore, the decision by Hoyle
et al. to estimate treatment duration as a function of progression-
free survival and short-term rates of discontinuation in clinical
studies may have been reasonable.
To evaluate uncertainty, the authors performed probabilistic
sensitivity analysis, which projected that dasatinib was more
costly than high-dose imatinib “in virtually all simulations,”
whereas nilotinib wasmore costly than high-dose imatinib in just
9% of simulations. This seemingly compelling finding, however,
does not address whether it makes sense that approximately 2.5
years of treatment with nilotinib and 6.5 years of treatment with
dasatinib provide the same level of effectiveness. The authors ac-
knowledge that the “duration of treatment is a key input.” Indeed,
they report that when progression-free survival for dasatinib was
assumed to be the same as for nilotinib, dasatinib became eco-
nomically dominant relative to high-dose imatinib.
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analysis represented uncertainty associated with estimates of
progression-free survival, not uncertainty about the true values
for treatment duration. This is unfortunate because some users of
cost-effectiveness analyses may rely too readily on findings from
probabilistic sensitivity analyses to gauge the reliability of a mod-
el’s results.
In accord with published recommendations for the conduct of
cost-effectiveness analyses, reporting on results from probabilis-
tic sensitivity analysis has increased dramatically over the last
decade [12]. Probabilistic sensitivity analysis is believed to repre-
sent an advance over traditional sensitivity analysis in which an-
alysts have discretion over which parameters are tested, the
ranges of parameter values applied, and their interpretation [13].
Experts, however, have called for greater awareness of the impor-
tance of structural uncertainty [14,15].
Structural uncertainty is typically described as uncertainty about
the functional formofamodel, suchas thenumberofhealthstates in
a Markov model or the statistical distribution used in a parametric
regressionmodel. In an evaluation of structural uncertainty, the an-
alyst makes the necessary changes to the model and reports the
results as a sensitivity analysis. In some cases, modifications to the
model structure may be straightforward. In other cases, a complete
overhaulmay be necessary and, given resource constraints, unlikely
to be done. When changes to a model’s structure have little impact
on the findings, the interpretation is simple. However, when struc-
tural changes alter a study’s qualitative findings (i.e., switch from
“cost-effective” to “not cost-effective” or vice versa), the analyst
should further investigate which structure is more appropriate.
In the analysis by Hoyle et al., an evaluation of structural un-
certainty would have required application of alternative sources
or assumptions to model treatment duration for nilotinib and da-
satinib. Ideally, the analyst has direct measures of treatment du-
ration. Such information was likely collected in previous clinical
studies of dasatinib and nilotinib, albeit not reported in published
articles. It is not clear whether the authors requested information
on treatment duration from the manufacturers of nilotinib and
dasatinib or the clinical investigators leading those studies. How-
ever,when access to important information is disallowed, itwould
be useful for authors to report such occurrences to justify the use
of alternative approaches to parameter estimation.
Evidence development for high-quality economic
evaluations
Multiple phase 2 and 3 trials are underway to evaluate the use of
dasatinib and nilotinib as first-line therapy in patients with newly
diagnosed chronic-phase CML. Early results indicate that these
second-generation TKIs produce faster and deeper cytogenetic
and molecular responses than do imatinib [16]. The National In-
stitute for Health and Clinical Excellence has already undertaken
an update of its review of first-line therapies for chronic-phase
CML. Also, as understanding of resistance to dasatinib, nilotinib,
and imatinib improves, discovery efforts are focused on overcom-
ing specific mutations. As the development of third-generation
TKIs progresses, another round of technology assessments for
second-line and third-line therapy will be in order.
Before thenext iterationof technology assessments, health econ-
omists should clarify the types of information that are necessary for
generating credible economicanalyses.Weshould conduct value-of-
information analyses to determinewhen a powerful economic argu-
ment can be made for ascertaining the data. Because treatment du-
rationwas a key input in the decisionmodel reported by Hoyle et al.,
it is likely that value-of-information estimates would surpass the
cost of measuring treatment duration directly.For years, health economists have argued for a seat at the study
design table. We routinely request integrated collection of data on
medical resource use, health utilities, and, in some cases, mea-
sures of patient time or productivity in clinical protocols. As our
field evolves and we becomemore knowledgeable about the main
determinants of cost-effectiveness in specific therapeutic areas,
wemust use the tools at our disposal tomake coherent arguments
about the value of collecting specific types of data.
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